Alnylam Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 05/27/2023
Alnylam Pharmaceuticals Inc Stock Forecast and Price Target
In recent months, seven notable analysts have provided yearlong price targets for Alnylam Pharmaceuticals Inc, with the average target coming in at $251.00. If it were to be achieved, this would result in a potential upside of approximately 33.33 percent from the most recent closing price in May, 2023. The high end is $415.00, and the low is $143.00. Although you may not be interested in ALNY stock, you should still be aware of its competitors.
33.33% Upside
Alnylam Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals Inc's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $200.74 – an increase of 100.00%. Over the next eight years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$154.35 | Buy/Sell | $178.79 | 16.94% |
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$425.79 | Buy/Sell | $333.19 | -6.06% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$37.60 | Buy/Sell | $47.96 | 40.03% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$111.07 | Buy/Sell | $99.57 | 6.24% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$63.82 | Buy/Sell | $80.99 | 30.05% |
Alnylam Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030
In the last four years, Alnylam Pharmaceuticals Inc's Revenue has grown from $219.75M to $1.04B – a 372.09% increase. Next year, analysts are expecting Revenue to reach $1.47B – an increase of 41.43%. Over the next eight years, the forecast is for Revenue to grow by 833.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$725.05 | Buy/Sell | $796.73 | 7.85% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$329.99 | Buy/Sell | $363.29 | -1.21% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$164.74 | Buy/Sell | $209.70 | 24.44% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.29 | Buy/Sell | $60.73 | 40.47% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$9.11 | Buy/Sell | $13.70 | 48.19% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$207.32 | Buy/Sell | $280.69 | 42.29% |
Alnylam Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last four years, Alnylam Pharmaceuticals Inc's Free Cash Flow has grown, rising from $-418.59M to $-779.38T – a growth of 186192355.62%. In the following year, the 8 analysts surveyed believe that Alnylam Pharmaceuticals Inc's Free Cash Flow will decrease by 100.00%, reaching $-420.13M. According to professionals, by 2030, Alnylam Pharmaceuticals Inc's Free Cash Flow will have decreased by 100.00%, falling down to $3.40B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$37.12 | Buy/Sell | $83.92 | 96.66% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$40.74 | Buy/Sell | $52.42 | 22.73% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$37.36 | Buy/Sell | $62.67 | 60.60% |
Alnylam Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030
In the last four years, Alnylam Pharmaceuticals Inc's Net Income has grown by 27.65%, rising from $-886.12M to $-1.13B. For the following year, the 12 analysts predict that Alnylam Pharmaceuticals Inc's Net Income will drop by 53.02%, reaching $-531.38M. In 2030, the professionals' prediction is that ALNY's Net Income will decrease by 467.74%, reaching $4.16B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$122.51 | Buy/Sell | $163.67 | 33.87% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$17.11 | Buy/Sell | $37.00 | 49.04% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$23.98 | Buy/Sell | $0.00 | 23.02% |
Alnylam Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last four years, Alnylam Pharmaceuticals Inc's EBITDA has decreased from $-922.26M to $-894.44M – a 3.02% drop! The next year, 8 experts forecast that Alnylam Pharmaceuticals Inc's EBITDA will decrease by 37.20%, reaching $-561.69M. In 2030, professionals predict that Alnylam Pharmaceuticals Inc's EBITDA will decrease by 584.60%, reaching $4.33B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$27.20 | Buy/Sell | $73.38 | -30.15% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£170.50 | Buy/Sell | £3.79 | -97.22% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$39.46 | Buy/Sell | $79.67 | 97.67% |
Alnylam Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals Inc has seen a decline in its EBIT, from $-939.43M to $-708.65M – a 24.57% decrease. In the next year, analysts believe that EBIT will reach $-745.30M – an increase of 5.17%. By 2030, professionals believe that Alnylam Pharmaceuticals Inc's EBIT will have decreased by 866.53%, falling to $5.43B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$44.14 | Buy/Sell | $41.00 | -0.32% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$10.81 | Buy/Sell | $12.60 | 15.63% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$33.62 | Buy/Sell | $35.50 | 1.13% |
Alnylam Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Alnylam Pharmaceuticals Inc's EPS has decreased from $-6.70 to $-6.14 – a 8.36% drop. Next year, analysts are expecting EPS to reach $-6.56 – an increase of 6.84%. In 2030, professionals predict that Alnylam Pharmaceuticals Inc's EPS will decrease by 540.72%, to $27.06.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$72.13 | Buy/Sell | $195.43 | 119.74% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$284.88 | Buy/Sell | $170.08 | -38.57% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$62.77 | Buy/Sell | $104.00 | -9.19% |
Site Navigation
.jpg)